ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW
Alvotech
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$5.03+0.03 (+0.60%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 50.3
- Dividend yield
- –
Share price
−$3.69 (−42.32%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Alvotech grew revenue 19.7% to $586.32M over fiscal 2025. Operating income rose 12.3% to $78.21M, moving the operating margin from 14.2% to 13.3%. Free cash flow was -$114.67M.
Revenue
$586.32M
+19.7% vs. a year earlier
Operating income
$78.21M
+12.3% vs. a year earlier
Free cash flow
-$114.67M
FY2025
EPS, diluted
$0.10
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 50.3
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $586.32M
- EPS, diluted
- $0.10
- Free cash flow
- -$114.67M
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
$586.32M+19.7% YoY
Gross profit
$350.76M+15.2% YoY
Operating income
$78.21M+12.3% YoY
EPS, diluted
$0.10
Free cash flow
-$114.67M
Reported period